Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:(6)394-424

The Christie NHS Foundation Trust. A profile of The Christie. 2020. (accessed 21 January 2020)

Cortes J, O'Shaughnessy J, Loesch D Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377:(9769)914-923

Homecare medicines: towards a vision for the future. 2011. (accessed 21 January 2020)

Eisai Inc. Halaven (eribulin) package insert/patient information leaflet. 2017. (accessed 21 January 2020)

Eisai Ltd. Halaven 0.44 mg/mL solution for injection, summary of product characteristics. 2015. (accessed 21 January 2020)

Hall M, Lloyd H. Evaluating patients' experiences of home and hospital chemotherapy. Cancer Nursing Practice. 2008; 7:(1)35-38

Handley NR, Bekelman JE. The oncology hospital at home. J Clin Oncol. 2019; 37:(6)448-452

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:(2)69-90

Lüthi F, Fucina N, Divorne N Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies. Support Care Cancer. 2012; 20:(3)575-581

National Clinical Homecare Association. NCHA code of practice for clinical homecare service providers. 2015. (accessed 21 January 2020)

National Homecare Medicines Committee. Good practice principles: provision of manufacturer funded homecare medicines services. Version 1. 2018. (accessed 21 January 2020)

NHS England. Five year forward view. 2014. (accessed 21 January 2020)

NHS England. Achieving world-class cancer outcomes: taking the strategy forward. 2016. (accessed 21 January 2020)

Building the case for clinical care in the home at scale: first report of the expert panel. 2015. (accessed 21 January 2020)

Raphaël R, Yves D, Giselle C, Magali M, Odile CM. Cancer treatment at home or in the hospital: what are the costs for French public health insurance?. Health Policy. 2005; 72:(2)141-148

Rischin D, White MA, Matthews JP A randomised crossover trial of chemotherapy in the home: patient preferences and cost anaiysis. Med J Aust. 2000; 173:(3)125-127

Royal Pharmaceutical Society. Professional standards for homecare services in England. 2013. (accessed 21 January 2020)

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016; 25:(1)16-27

Tralongo P, Ferraù F, Borsellino N. Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag. 2011; 7:387-392

Vanguard Innovation (Greater Manchester Cancer). About us. (accessed 21 January 2020)

Systemic anti-cancer therapy delivery in the home: a service model

28 May 2020
Volume 29 · Issue 10


The Christie NHS Foundation Trust is a leader in adapting patient care in response to treatment advances and new patient-centred care/efficiency initiatives. Due to extended waiting times in cancer clinics, The Christie developed an at-home treatment service to help reduce the pressure on clinics and improve patient experience. This article provides a detailed examination of the requirements necessary to successfully develop a home service for the delivery of systemic anticancer treatment. The authors discuss the criteria used to identify suitable at-home treatments, as well as necessary resources and equipment. The success of the Christie at Home service was examined using a patient survey to assess the standard of this care. Details are given regarding the challenges of implementing a homecare service and potential future challenges. As an example, systemic treatment with eribulin as a ‘Christie at Home’ therapy demonstrates the practicalities of introduction of new therapies in a homecare service.

The Christie NHS Foundation Trust—the largest single-site cancer centre in Europe—is a tertiary specialist cancer centre based in Manchester, serving a population of approximately 3 million people, treating all types of solid tumours and haematologic cancers in adults (The Christie NHS Foundation Trust, 2020). The Christie is a leader in adapting patient care in response to treatment advances and policy changes, developing models for the evolving NHS, and responding to patient-centred care and efficiency initiatives (NHS England, 2016; Vanguard Innovation, 2020).

In 2015, nurses at Christie outpatient clinics began to report extended on-the-day waiting times for patients due to an increase in numbers needing treatment. As a result, The Christie began to explore ways to adapt its services to improve clinic capacity and patient experience; around this time, expanding out-of-hospital care was targeted as a priority for NHS England (2014), and homecare was predicted to have wide-ranging benefits, including reduced pressure on hospitals and improved adherence to therapies, quality of life, and patient engagement with treatment (Outram et al, 2015). As such, the team identified homecare as a service that could potentially reduce pressure on clinics, and would also provide a financial benefit via a value-added tax (VAT) saving because homecare medicines are exempt from VAT (Hackett, 2011). The resulting VAT saving would then help cover the cost of resources needed to run the homecare service (Hackett, 2011). Trastuzumab, a targeted therapy for breast cancer, was already being delivered at home, and this offered a platform for the expansion of treatment site options by The Christie.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content